UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) ~~OF THE~~

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) ~~October~~November 2818, 2025

AXALTA COATING SYSTEMS LTD.

(Exact name of registrant as specified in its charter)

Bermuda	001-36733	~~001-36733~~	98-1073028	~~98-1073028~~
(State or other jurisdictionof incorporation)		(CommissionFile Number)		(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)		(IRS Employer Identification No.)

1050 Constitution Avenue, Philadelphia, ~~Pennsylvania~~PA 19112

(Address of principal executive offices) (Zip Code)

(855) 547-1461

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Common Shares, $1.00 par value

AXTA

New York Stock Exchange

(Title of class)

(Trading

symbol)

(Exchange on

which registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2 1.~~02.~~01 ~~Results~~Entry ofinto ~~Operations~~a ~~and~~Material ~~Financial~~Definitive ~~Condition~~Agreement.

OnMerger ~~October~~Agreement 28, 2025, Axalta Coating Systems Ltd. ("Axalta") issued a press release and posted an earnings call presentation to its website reporting its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

~~Item~~On 8November 18, 2025, Axalta Coating Systems Ltd.01, ~~Other~~an ~~Events~~exempted company incorporated under the laws of Bermuda (“Axalta” or the “Company”), entered into a Merger Agreement (the “Merger Agreement”) with Akzo Nobel N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of the Netherlands (“AkzoNobel” and, after giving effect to the Merger, “MergeCo”).

OnThe ~~October~~Merger 28Agreement provides for, ~~2025~~among other things, the combination of Axalta ~~Coating~~and ~~Systems~~AkzoNobel ~~Dutch~~in ~~Holding~~an all-stock merger Bof ~~B.V.~~equals upon the terms and ~~Axalta~~subject ~~Coating~~to ~~Systems~~the ~~U.S.~~conditions ~~Holdings,~~set ~~Inc~~forth therein., asThe ~~borrowers,~~board ~~certain~~of ~~lenders~~directors ~~party~~of ~~thereto~~the ~~and~~Company ~~Barclays~~(the ~~Bank~~“Company ~~PLC,~~Board”) asand ~~administrative~~both ~~agent~~the supervisory board and athe ~~lender,~~board ~~entered~~of ~~into~~management of AkzoNobel (collectively, the ~~Seventeenth~~“AkzoNobel ~~Amendment~~Boards”) tohave ~~Credit~~each unanimously approved the Merger Agreement, the Merger (~~“Amendment~~as ~~No.~~defined ~~17”~~below), ~~which~~and ~~amended~~the ~~that~~other ~~certain~~transactions ~~Credit~~contemplated by the Merger Agreement, ~~dated~~including, asin ofthe ~~February~~case 1of AkzoNobel, ~~2013~~the issuance of AkzoNobel Ordinary Shares (as ~~amended~~defined below) as Merger Consideration (as defined below) and, in the ~~"Credit~~case ~~Agreement").~~of ~~Amendment~~Axalta, ~~No.~~the 17amendment ~~amended~~to the ~~Credit~~Company’s Second Amended and Restated Bye-laws as set forth in the Merger Agreement. toMergeCo ~~permit~~will be dual-headquartered in Amsterdam, the ~~use~~Netherlands ofand ~~borrowings~~Philadelphia, ~~under~~Pennsylvania and listed on the ~~Credit~~New ~~Agreement~~York toStock ~~fund~~Exchange ~~repurchases~~and ofEuronext ~~common~~Amsterdam ~~shares~~(with ofdelisting ~~Axalta~~from ~~subject~~Euronext Amsterdam to be effected on or as soon as practicable following the ~~conditions~~effective ~~set~~time ~~forth~~of ~~therein~~the Merger (the “Effective Time”)).

ASubject ~~copy~~to ofthe ~~Amendment~~terms ~~No.~~and 17conditions isset ~~attached~~forth ~~hereto~~in the Merger Agreement, (i) AkzoNobel will incorporate an exempted company under the laws of Bermuda as ~~Exhibit~~a ~~10.1~~wholly owned subsidiary (“Merger Sub”), (ii) Merger Sub will be merged with and isinto ~~incorporated~~the byCompany ~~reference~~(the ~~herein.~~“Merger”), ~~The~~with ~~foregoing~~the ~~description~~Company continuing as the surviving company of ~~Amendment~~the ~~No.~~Merger 17(the ~~does~~“Surviving ~~not~~Company”) ~~purport~~and toas bea ~~complete~~wholly owned subsidiary of AkzoNobel, and is(iii) at ~~subject~~the toEffective Time, each outstanding and ~~qualified~~issued inordinary ~~its~~share ~~entirety~~of bythe Company, par value $1.00 per share (a “Company Ordinary Share”) (other than any Company Ordinary Shares owned by the ~~full~~Company ~~text~~as treasury shares and any Company Ordinary Shares owned by AkzoNobel, Merger Sub or any other direct or indirect wholly owned subsidiary of ~~Amendment~~AkzoNobel), Nowill be automatically converted into the right to receive 0.6539 17(the “Exchange Ratio”) duly authorized, validly issued and fully paid AkzoNobel ordinary shares, par value of €0.50 per share (“AkzoNobel Ordinary Shares”) (such AkzoNobel Ordinary Shares, the “Merger Consideration”).

~~Item~~Subject 9to the terms and conditions set forth in the Merger Agreement, prior to the Effective Time, AkzoNobel will declare and pay a special cash dividend (the “Pre-Completion Distribution”) to AkzoNobel shareholders.01 The aggregate amount of the Pre-Completion Distribution will be €2.5 billion ~~Financial~~minus ~~Statements~~the aggregate amount of any regular annual and ~~Exhibits~~interim dividends of €1.98 per Akzo Nobel Ordinary Share per year declared by AkzoNobel after the date of the Merger Agreement and with record dates in 2026 prior to the record date of the Pre-Completion Distribution, subject to any applicable withholding tax.

Under the terms of the Merger Agreement, each equity award of the Company, consisting of stock options, restricted stock units and performance share units, that is outstanding immediately prior to the Effective Time will generally be converted into an equivalent AkzoNobel equity award subject to the same terms and conditions as applied prior to the Effective Time, except that performance share units will be converted into solely time-vesting restricted stock units. The number of AkzoNobel Ordinary Shares subject to each converted equity award will be equal to the number of Company Ordinary Shares subject to such award immediately prior to the Effective Time, with the number of Company Ordinary Shares subject to any performance share unit determined based on the greater of target and actual performance measured through the Effective Time, multiplied by the Exchange Ratio, and the exercise price of each converted stock option will be equal to the exercise price of the Company stock option divided by the Exchange Ratio. Notwithstanding the foregoing, each restricted stock unit or performance share unit of the Company that (i) is vested as of immediately prior to the Effective Time, (ii) is held by a non-employee member of the Company Board or a former service provider of the Company, or (iii) is subject to a performance period that has been completed as of immediately prior to the Effective Time, in each case, will instead be converted into the right to receive the Merger Consideration, with any performance conditions deemed achieved, (a) in the case of awards held by former service providers for which the performance period has not yet been completed, at the greater of target and actual performance measured through the Effective Time, and (b) in the case of awards for which the performance period has been completed, based on actual performance. Furthermore, each stock option that is held by a former service provider of the Company will be converted into the right to receive a number of AkzoNobel Ordinary Shares equal to the number of Company Ordinary Shares subject to such stock option immediately prior to the Effective Time (less the number of shares with a value equal to the aggregate exercise price of such stock option) multiplied by the Exchange Ratio, with any such stock option that has a per share exercise price that is equal to or greater than the closing price of a Company Ordinary Share on the trading day immediately preceding the Effective Time cancelled without consideration.

Additionally, under the terms of the Merger Agreement, each AkzoNobel equity award, consisting of restricted stock units, performance share units and conditional rights under AkzoNobel’s share matching program, that is outstanding immediately prior to the Effective Time will remain outstanding on and following the Effective Time and will generally be subject to the same terms and conditions as applied prior to the Effective Time, except that performance share units will be converted into solely time-vesting restricted stock units, with the performance conditions deemed achieved at the greater of target and actual performance measured through the Effective Time.

Pursuant to the terms of the Merger Agreement, immediately following the Effective Time, MergeCo will have a one-tier board of directors (the “MergeCo Board”) comprised of eleven directors, consisting of (i) four directors to be nominated by Axalta (the “Axalta Nominees”), one of whom shall be Rakesh Sachdev and one of whom shall be Chris Villavarayan, (ii) four directors to be nominated by AkzoNobel (the “AkzoNobel Nominees”), one of whom shall be Ben Noteboom and one of whom shall be Grégoire Poux-Guillaume and (iii) three independent directors to be jointly nominated by Axalta and AkzoNobel (the “Joint Nominees”, and, together with the Axalta Nominees and the AkzoNobel Nominees, the “MergeCo Board Nominees”). Each of the MergeCo Board Nominees will be nominated to serve an initial three-year term (with the end of such term adjusted as necessary to coincide with the date of the first annual general meeting of MergeCo’s shareholders held after the third anniversary of closing). At such general meeting of MergeCo’s shareholders (i) the Axalta Nominees (or their replacements) and the AkzoNobel Nominees (or their replacements) will be put up for election to serve a two-year term and (ii) the Joint Nominees (or their replacements) will be put up for election to serve a one-year term. At the annual general meeting of MergeCo’s shareholders held after the fourth anniversary of closing, the Joint Nominees (or their replacements) will be put up for election to serve another one-year term. As of and following the first annual general meeting of MergeCo’s shareholders held after the fifth anniversary of closing, all directors will be put up for election to serve a one-year term (without restricting the MergeCo Board from deciding otherwise).

Mr. Poux-Guillaume, the current chief executive officer of AkzoNobel, will be appointed to serve as the chief executive officer of MergeCo, Mr. Sachdev, the current chair of the board of directors of the Company, will be appointed to serve as the non-executive chair of the MergeCo Board, Mr. Villavarayan, the current chief executive officer of the Company, will be appointed to serve as the deputy chief executive officer of MergeCo, Mr. Noteboom, the current chairman of the supervisory board of AkzoNobel, will be appointed to serve as the non-executive vice-chair of the MergeCo Board, and Carl Anderson, the Company’s current senior vice president and chief financial officer, will be appointed to serve as the chief financial officer of MergeCo.

The Company and AkzoNobel each have made customary representations, warranties and covenants in the Merger Agreement, in each case generally subject to customary qualifications. Among other things, each of the Company and AkzoNobel has agreed, subject to certain exceptions, to use its reasonable best efforts to conduct its business in the ordinary course of business, from the date of the Merger Agreement until the Effective Time, and (i) not to take certain actions prior to the Effective Time without the prior written consent of the other party, (ii) not to solicit proposals relating to alternative business combination transactions and (iii) subject to customary exceptions, not to engage in discussions or negotiations regarding, or provide confidential information in connection with, any such alternative business combination transactions. In addition, the parties have agreed to use their respective reasonable best efforts to take any and all actions reasonably necessary to obtain each regulatory approval necessary to complete the Merger (the “Regulatory Clearances”) as soon as reasonably practicable. In addition, each party has agreed to consent to any divestiture, sale, disposition or other structural or conduct remedy unless such actions would be materially burdensome to such party.

The obligations of the Company and AkzoNobel to consummate the Merger are conditioned on the satisfaction or waiver of certain conditions, including (i) at a general meeting of the shareholders of the Company, (a) the approval and adoption of the Merger, the Merger Agreement, the Bermuda statutory merger agreement and the transactions contemplated thereby and (b) the approval of the amendment to the bye-laws of the Company, (ii) at a general meeting of shareholders of AkzoNobel, (a) the approval of AkzoNobel entering into the Merger and the other actions contemplated by the Merger Agreement, (b) the approval of the amendment of AkzoNobel’s articles of association to reflect the governance terms set forth in the Merger Agreement, with effect as of immediately following the Effective Time, (c) the approval of issuance of the Merger Consideration and exclusion of pre-emption rights in connection therewith, and (d) the appointment or reappointment, as applicable, of the MergeCo Board Nominees, with effect as of immediately following the Effective Time, in the case of each of clauses (a) through (d), by holders of ordinary shares of AkzoNobel, (iii) declaration and payment of the Pre-Completion Distribution, (iv) completion of the consultation process with AkzoNobel’s central works council in accordance with the terms of the Merger Agreement, (v) the approval of the Merger Consideration for listing on the New York Stock Exchange, (vi) AkzoNobel having made publicly available a document in accordance with Regulation (EU) 2017/1129 as required in connection with the listing on Euronext Amsterdam of the AkzoNobel ordinary shares to be issued in the Merger, (vii) the registration statement on Form F-4 with respect to the Merger Consideration having been declared effective by the U.S. Securities and Exchange Commission (“SEC”), (viii) the expiration or termination of the applicable waiting periods

under the Hart-Scott-Rodino Act and the receipt of certain other clearances, approvals and consents under certain applicable foreign antitrust and regulatory laws, in each case, without the imposition of any terms, conditions or consequences that are materially burdensome, and (ix) other customary conditions for a transaction of this type, such as (a) the absence of any legal restraint prohibiting the consummation of the transactions contemplated by the Merger Agreement, (b) the accuracy of the Company and AkzoNobel’s representations and warranties, subject to customary qualifications, (c) compliance by the Company and AkzoNobel, respectively, in all material respects with its obligations under the Merger Agreement and (d) the absence of a material adverse effect on the Company or AkzoNobel.

The Merger Agreement contains certain termination rights for the Company and AkzoNobel, including (i) if the Merger is not consummated on or before the “outside date” of May 18, 2027 (subject to extension to November 18, 2027 under certain circumstances in the event that any Regulatory Clearance has not been obtained), (ii) if the required approval of the Company shareholders or the AkzoNobel shareholders is not obtained, (iii) subject to compliance with certain terms of the Merger Agreement, in order to enter into a definitive agreement providing for a superior proposal, (iv) if the other party materially breaches its representations, warranties or covenants and fails to cure such breach, (v) if any injunction or order permanently prohibiting the Merger has become final and non-appealable or (vi) if, prior to the applicable shareholders’ meeting, the Company Board or either of the AkzoNobel Boards, as applicable, changes its recommendation or fails to reaffirm such recommendation in certain circumstances.

In the event of a termination of the Merger Agreement under certain specified circumstances, including (i) termination by the Company to enter into an agreement providing for a superior proposal, (ii) a termination by AkzoNobel following a change in recommendation by the Company Board or (iii) the Company has entered into an agreement providing for a superior proposal within twelve months following the termination of the Merger Agreement in certain circumstances, the Company may be required to pay AkzoNobel a termination fee equal to €150 million. In the event of a termination of the Merger Agreement under certain specified circumstances, including (i) termination by AkzoNobel to enter into an agreement providing for a superior proposal, (ii) a termination by the Company following a change in recommendation by either of the AkzoNobel Boards or (iii) AkzoNobel has entered into an agreement providing for a superior proposal within twelve months following the termination of the Merger Agreement in certain circumstances, AkzoNobel may be required to pay the Company a termination fee equal to €150 million.

The foregoing description of the Merger Agreement is only a summary, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement, which is attached as Exhibit 2.1 to this report and incorporated by reference herein. The Merger Agreement and the above description have been included to provide investors and security holders with information regarding the terms of the Merger Agreement. They are not intended to provide any other factual information about the Company, AkzoNobel or their respective subsidiaries or affiliates or equityholders. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of that agreement and as of specific dates; were solely for the benefit of the parties to the Merger Agreement; and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made by each contracting party to the other for the purposes of allocating contractual risk between them that differ from those applicable to investors. Investors should be aware that the representations, warranties and covenants or any description thereof may not reflect the actual state of facts or condition of the Company, AkzoNobel or any of their respective subsidiaries, affiliates, businesses, or equityholders and investors should not rely on them as statements of fact. Moreover, information concerning the subject matter of the representations, warranties, and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in public disclosures by the Company or AkzoNobel. Accordingly, investors should read the representations and warranties of the Company or AkzoNobel and their respective subsidiaries in the Merger Agreement not in isolation, but only in conjunction with the other information that the respective companies include in reports, statements and other filings they make with the SEC.

Stichting Support Agreement

In connection with the Merger Agreement, AkzoNobel and the Company have entered into that certain Support Agreement (the “Support Agreement”) with Stichting AkzoNobel, an entity that holds all of the issued and outstanding AkzoNobel priority shares, par value of €400 per share (“AkzoNobel Priority Shares”). Under the Support Agreement, Stichting AkzoNobel has irrevocably agreed, among other things and subject to the terms and conditions of the Support Agreement, to cooperate with the implementation of the Merger where required, including to (i) give its prior approval to the proposal to amend AkzoNobel’s articles of association in accordance with the MergeCo articles of association, pursuant to which, among other things, the AkzoNobel Priority Shares will be converted into AkzoNobel Ordinary Shares and all rights that accrue to Stichting AkzoNobel as sole holder of the AkzoNobel Priority Shares will lapse and (ii) vote all of the AkzoNobel Priority Shares in favour of the resolutions to be presented to AkzoNobel shareholders at the general meeting of AkzoNobel shareholders to be held in connection with the Merger (including to approve the Merger) and against any resolution or other vote that would, or would reasonably be expected to, delay, prevent, condition or impede, in whole or in part, the consummation of the transactions contemplated by the Merger Agreement, including the Merger.

The foregoing description of the Support Agreement is only a summary, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Support Agreement, which is included as Schedule 2 of the Merger Agreement attached as Exhibit 2.1 to this report and incorporated by reference herein.

Item 8.01 Other Events

On November 18, 2025, the Company and AkzoNobel issued a joint press release to announce the execution of the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Additionally, on November 18, 2025, the Company and AkzoNobel issued a joint investor presentation, a copy of which is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d)

Exhibits

Exhibit No.		Description
ExhibitNumber	Description
10.1		Seventeenth Amendment to Credit Agreement, dated as of October 28, 2025, among Axalta Coating Systems Dutch Holding B B.V., Axalta Coating Systems U.S. Holdings, Inc., certain lenders party thereto and Barclays Bank PLC, as administrative agent and a lender.
2.1	Merger Agreement, by and among Akzo Nobel N.V., and Axalta Coating Systems Ltd., dated November 18, 2025.*
99		Press Release dated October 28, 2025
99.1	Joint Press Release of Axalta Coating Systems Ltd. and Akzo Nobel N.V., dated November 18, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)
99.2	Joint Investor Presentation of Axalta Coating Systems Ltd. and Akzo Nobel N.V.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

*	Certain schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Axalta Coating Systems Ltd. hereby agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

General restrictions

This communication is not for release, publication, or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication, or distribution would be unlawful.

This communication is not a prospectus and the information in this communication is not intended to be complete. This communication is for informational purposes only and is not intended to be and shall not constitute a solicitation of any vote or approval, or an offer to buy or sell, or the solicitation of an offer to buy or sell, any securities, or an invitation or recommendation to subscribe for, acquire or buy securities of AkzoNobel or Axalta or any other financial products or securities, in any place or jurisdiction, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended (the “Securities Act”).

Any decision to purchase, subscribe for, otherwise acquire, sell or otherwise dispose of any securities must be made only on the basis of the information contained in and incorporated by reference into the prospectus with respect to the shares to be allotted by AkzoNobel in the proposed transaction once published. A prospectus in relation to the proposed transaction described in this communication is expected to be published in due course.

The distribution of this communication may, in some countries, be restricted by law or regulation. Accordingly, persons who come into possession of this document should inform themselves of and observe these restrictions. To the fullest extent permitted by applicable law, AkzoNobel and Axalta disclaim any responsibility or liability for the violation of any such restrictions by any person. Neither AkzoNobel, nor Axalta, nor any of their advisors assume any responsibility for any violation by any person of any of these restrictions. Shareholders of AkzoNobel and Axalta, respectively, with any doubt as to their position should consult an appropriate professional advisor without delay.

This communication is addressed to and directed only at, persons who are outside the United Kingdom or, in the United Kingdom, at persons who are: (i) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (ii) persons falling within Article 49(2)(a) to (d) of the Order, or (iii) persons to whom it may otherwise lawfully be communicated pursuant to the Order (all such persons together being referred to as, “Relevant Persons”). This communication is directed only at Relevant Persons. Other persons should not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with such persons. Solicitations resulting from this communication will only be responded to if the person concerned is a Relevant Person.

Additional Information and Where to Find It

In connection with the proposed transaction between AkzoNobel and Axalta, AkzoNobel will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4, which will include a proxy statement of Axalta that also constitutes a prospectus with respect to the shares to be offered by AkzoNobel in the proposed transaction. The definitive proxy statement/prospectus will be sent to the shareholders of Axalta. Each of AkzoNobel and Axalta will also file other relevant documents in connection with the proposed transaction. This communication is not a substitute for any registration statement, proxy statement/prospectus or other documents AkzoNobel and/or Axalta may file with the SEC or any other competent regulator in connection with the proposed transaction. This communication does not contain all the information that should be considered concerning the proposed transaction and is not intended to form the basis of any investment decision or any other decision in respect of the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISIONS, INVESTORS, STOCKHOLDERS AND SHAREHOLDERS OF AKZONOBEL AND AXALTA ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT/PROSPECTUS, AS APPLICABLE, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT AKZONOBEL, AXALTA, THE PROPOSED TRANSACTION AND RELATED MATTERS. The registration statement and proxy statement/prospectus and other relevant documents filed by AkzoNobel and Axalta with the SEC, when filed, will be available free of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed with the SEC from Axalta’s investor relations webpage at https://ir.axalta.com/sec-filings/all-sec-filings or from AkzoNobel’s investor relations webpage at https://www.akzonobel.com/en/investors.

The contents of this communication should not be construed as financial, legal, business, investment, tax or other professional advice. Each recipient should consult with its own professional advisors for any such matter and advice.

Participants in the Solicitation

This communication is not a solicitation of proxies in connection with the proposed transaction. However, under SEC rules, AkzoNobel, Axalta and certain of their respective directors and executive officers and other members of their respective management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, including a description of their direct or indirect interests in the proposed transaction, by security holdings or otherwise, will be set forth in the proxy statement/prospectus and other relevant materials when it is filed with the SEC. Information regarding the directors and executive officers of Axalta is contained in Axalta’s proxy statement for its 2025 annual meeting of stockholders, filed with the SEC April 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on February 13, 2025, subsequent statements of beneficial ownership on file with the SEC, including the Initial Statements of Beneficial Ownership on Form 3, Statements of Change in Ownership on Form 4 or Annual Statements of Beneficial Ownership on Form 5 filed with the SEC on: 2/19/2025, 2/19/25, 2/19/2025, 2/19/25, 2/19/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 8/5/2025, 8/18/2025, 8/21/2025, 9/23/2025 and 9/23/2025, and other filings made from time to time with the SEC. Information about AkzoNobel’s supervisory board members and members of the board of management is set forth in AkzoNobel’s latest annual report, as filed with the AFM, the Dutch trader register and on its website at https://www.akzonobel.com/en/investors/results-center, and as updated from time to time via filings made by AkzoNobel with the AFM. Additional information regarding the interests of persons who

may, under the rules of the SEC, be deemed participants in the solicitation of Axalta security holders in connection with the proposed transaction, which may, in some cases, be different than those of Axalta’s shareholders generally, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus and other relevant materials when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Cautionary Statement Concerning Forward-Looking Statements

This communication contains forward-looking statements as that term is defined in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, regarding, among other things, statements about management’s expectations of AkzoNobel’s and Axalta’s future operating and financial performance, product development, market position, and business strategy. Such forward-looking statements can sometimes be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “potential,” “seeks,” “aims,” “projects,” “predicts,” “is optimistic,” “intends,” “plans,” “estimates,” “targets,” “anticipates,” “continues” or other comparable terms or negatives of these terms, but not all forward-looking statements include such identifying words. You are cautioned not to rely on these forward-looking statements. Forward-looking statements are based upon current plans, estimates and expectations that are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. We can give no assurance that such plans, estimates or expectations will be achieved and therefore, actual results may differ materially from any plans, estimates or expectations in such forward-looking statements. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include: a condition to the closing of the proposed transaction may not be satisfied; the occurrence of any event that can give rise to termination of the proposed transaction; a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; AkzoNobel and Axalta are unable to achieve the synergies and value creation contemplated by the proposed transaction; AkzoNobel and Axalta are unable to promptly and effectively integrate their businesses; management’s time and attention is diverted on transaction related issues; the possibility that competing offers or acquisition proposals may be made; disruption from the proposed transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of AkzoNobel or Axalta decline following the proposed transaction; legal proceedings are instituted against AkzoNobel or Axalta, including resulting expense or delay; AkzoNobel or Axalta is unable to retain or hire key personnel; the communication or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of AkzoNobel or Axalta or on AkzoNobel’s or Axalta’s operating results; evolving legal, regulatory and tax regimes; changes in economic, financial, political and regulatory conditions, in the Netherlands, the United States and elsewhere, and other factors that contribute to uncertainty and volatility, natural and man-made disasters, civil unrest, pandemics (e.g., the coronavirus (COVID-19) pandemic), geopolitical uncertainty, and conditions that may result from legislative, regulatory, trade and policy changes associated with the current or subsequent United States or Netherlands administration; the ability of AkzoNobel or Axalta to successfully recover from a disaster or other business continuity problem due to a hurricane, flood, earthquake, terrorist attack, war, pandemic, security breach, cyber-attack, power loss, telecommunications failure or other natural or man-made event, including the ability to function remotely during long-term disruptions; the impact of public health crises, such as pandemics and epidemics and any related company or governmental policies and actions to protect the health and safety of individuals or governmental policies or actions to maintain the functioning of national or global economies and markets, including any quarantine, “shelter in place,” “stay at home,” workforce reduction, social distancing, shut down or similar actions and policies; actions by third parties, including government agencies; the risk that disruptions from the proposed transaction will harm AkzoNobel’s or Axalta’s business, including current plans and operations and/or divert management’s attention from AkzoNobel’s or Axalta’s ongoing business operations; certain restrictions during the pendency of the acquisition that may impact AkzoNobel’s or Axalta’s ability to pursue certain business opportunities or strategic transactions; AkzoNobel’s or Axalta’s ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; the risks and uncertainties discussed in AkzoNobel’s latest annual report as filed with the AFM, the Dutch trader register and on its website at https://www.akzonobel.com/en/investors/results-center; and the risks and uncertainties discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in Axalta’s reports filed with the SEC. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the proxy statement/prospectus. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. We caution you not to place undue reliance on any of these forward-looking statements as they are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of new markets or market segments in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Except as required by law, neither AkzoNobel nor Axalta assumes any obligation to update or revise the information contained herein, which speaks only as of the date hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		AXALTA COATING SYSTEMS LTD.	~~AXALTA COATING SYSTEMS LTD.~~
Date:	October 28, 2025		By:	/s/ Carl D. Anderson II
Date: November 18, 2025		By:	/s/ Alex Tablin-Wolf
				Carl D. Anderson II
			Alex Tablin-Wolf
				Senior Vice President and Chief Financial Officer
			Senior Vice President, General Counsel & Corporate Secretary

Filing Compare · Axalta Coating Systems Ltd.